Brokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $62.71

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has earned a consensus rating of “Buy” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $65.1429.

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group upped their target price on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, June 29th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the transaction, the insider owned 65,623 shares of the company’s stock, valued at $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the transaction, the chief executive officer owned 48,565 shares in the company, valued at $2,623,481.30. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 628,427 shares of company stock valued at $32,833,228. Insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Osaic Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International in the second quarter worth approximately $31,000. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $34,000. Smartleaf Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Down 0.9%

NASDAQ KNSA opened at $61.11 on Friday. The company has a market capitalization of $4.70 billion, a P/E ratio of 67.90 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 12-month low of $26.27 and a 12-month high of $67.53. The firm has a 50-day moving average price of $56.32 and a two-hundred day moving average price of $49.11.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.11 earnings per share. Equities analysts expect that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.